Regulated cell death (RCD) in cancer: key pathways and targeted therapies

Fu, Peng; Liao, Minru; Qin, Rui; Zhu, Shiou; Peng, Cheng; Fu, Leilei; Chen, Yi; Han, Bo

doi:10.1038/s41392-022-01110-y

Cited by 379 publications

(220 citation statements)

References 487 publications

Supporting

Mentioning

154

Contrasting

Order By: Relevance

“…RCD, or the cell suicide pathway, plays a critical role in organismal development and homeostasis. The most prominent and well-defined form of RCD is apoptosis, which serves as a defense mechanism against the emergence of cancer cells [ 4 ] and serves as a homeostatic mechanism to maintain cell populations in tissues [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting Apoptosis in AML: Where Do We Stand?

Krawiec

Strzałka²,

Czemerska³

et al. 2022

Cancers

View full text Add to dashboard Cite

More than 97% of patients with acute myeloid leukemia (AML) demonstrate genetic mutations leading to excessive proliferation combined with the evasion of regulated cell death (RCD). The most prominent and well-defined form of RCD is apoptosis, which serves as a defense mechanism against the emergence of cancer cells. Apoptosis is regulated in part by the BCL-2 family of pro- and anti-apoptotic proteins, whose balance can significantly determine cell survival. Apoptosis evasion plays a key role in tumorigenesis and drug resistance, and thus in the development and progression of AML. Research on the structural and biochemical aspects of apoptosis proteins and their regulators offers promise for new classes of targeted therapies and strategies for therapeutic intervention. This review provides a comprehensive overview of current AML treatment options related to the mechanism of apoptosis, particularly its mitochondrial pathway, and other promising concepts such as neddylation. It pays particular attention to clinically-relevant aspects of current and future AML treatment approaches, highlighting the molecular basis of individual therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting Apoptosis in AML: Where Do We Stand?

Krawiec

Strzałka²,

Czemerska³

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…We conducted a PubMed search for ‘necroptosis and cancer’ and found that the number of articles in 2021 was the highest and continued to increase. A high-quality review published in August 2022 by Peng et al illustrates the important role of various programmed cell death pathways in cancer, including necroptosis ( Peng et al, 2022 ). Necroptosis follows signal regulation within tumor cells, and after TNF-α binds to TNFR1 on the plasma membrane, downstream protein molecules are recruited to form complex I ( Ofengeim and Yuan, 2013 ).…”

Section: Discussionmentioning

confidence: 99%

Bibliometric analysis of publications on necroptosis from 2001 to 2021

Liu

Zhou

Wang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Background: Necroptosis plays an important role in inflammation, cancer, and neurodegenerative diseases. In recent years, the number of studies related to necroptosis has increased and research has become increasingly in-depth. This study aimed to summarize the research conducted since 2001 to discover hotspots and trends in the field of necroptosis.Methods: The Web of Science Core database was used to identify global publications on necroptosis from 2001 to 2021. Bibliometric analysis was performed using Rstudio, VOSviewer, and CiteSpace.Results: The number of publications related to necroptosis gradually increased from 2001 to 2021. Vandenabeele P had the most publications at 45. Yuan JY had the most citations at 5,901. Necroptosis research has been dominated by China and Chinese institutions. Cell Death and Disease had the highest number of related publications among the examined journals. Seven of the top 10 most cited papers had more than 500 citations. Necroptosis, cell death, autophagy, injury, cancer, activated B cell nuclear factor kappa-light chain enhancer, and oxidative stress were important keywords in keyword analysis. Recent research has increasingly focused on breast cancer, receptor-interacting serine/threonine protein kinase 1, modulation, pseudokinase mixed lineage kinase domain-like protein, membrane, protection, and cycle.Conclusion: Interest in necroptosis-related research continues to increase steadily, and there is close cooperation between countries and institutions in the field of necroptosis. The study of necroptosis-related molecules and mechanisms, and the relationship between necroptosis and cancer, may be hotspots and directions in future research.

show abstract

“…Cell death inducers have always been an important research field in cancer treatment strategies [ 843 ]. Mechanically, the available antitumor drugs induce cell cycle arrest or cell death unexceptionally.…”

Section: Introductionmentioning

confidence: 99%

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

et al. 2022

View full text Add to dashboard Cite

The United States Food and Drug Administration (US FDA) has always been a forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs (excluding vaccines, cell-based therapies, and gene therapy products) have been approved as new molecular entities (NMEs) or biologics license applications (BLAs). A total of 228 of these 1050 drugs were identified as cancer therapeutics or cancer-related drugs, and 120 of them were classified as therapeutic drugs for solid tumors according to their initial indications. These drugs have evolved from small molecules with broad-spectrum antitumor properties in the early stage to monoclonal antibodies (mAbs) and antibody‒drug conjugates (ADCs) with a more precise targeting effect during the most recent decade. These drugs have extended indications for other malignancies, constituting a cancer treatment system for monotherapy or combined therapy. However, the available targets are still mainly limited to receptor tyrosine kinases (RTKs), restricting the development of antitumor drugs. In this review, these 120 drugs are summarized and classified according to the initial indications, characteristics, or functions. Additionally, RTK-targeted therapies and immune checkpoint-based immunotherapies are also discussed. Our analysis of existing challenges and potential opportunities in drug development may advance solid tumor treatment in the future.

show abstract

Regulated cell death (RCD) in cancer: key pathways and targeted therapies

Cited by 379 publications

References 487 publications

Targeting Apoptosis in AML: Where Do We Stand?

Targeting Apoptosis in AML: Where Do We Stand?

Bibliometric analysis of publications on necroptosis from 2001 to 2021

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Contact Info

Product

Resources

About